All News
ACR 2018 - Day 4 Report
Highlights from Tuesday and Wednesday (days 3 and 4) from the ACR annual meeting include: the important and impactful abstracts covered by the Rheumatology Roundup session; upadacitinib clinical trials; and the baricitinib CV and VTE safety analysis.
Read Article
2789 Ph3 Apremilast for Behcet’s oral ulcers: significantly lower number of OU (P≤0.0015) &reduction in OU pain (P≤0.0035) vs PBO at wks 1-12. APR efficacy sustained at wk28: 62% pts achieved complete response of OU &70% relative
reduction in OU pain from BL. #acr18 @rheumnow
Olga Petryna DrPetryna ( View Tweet)
RheumNow expanded twitter coverage of the ACR 2018 Annual meeting sponsored in part by Eli Lilly. All content chosen and distributed by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
RheumNow expanded twitter coverage of the ACR 2018 Annual meeting sponsored in part by Novartis. All content chosen and distributed by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
It may be the last day of #ACR18 but huge interest for talk by @Deepakarao (standing room only!) Really interesting presentation showing PD-1hi CXCR5- T peripheral helper cells are significantly expanded in #SLE In particular in those with high SLEDAI and dsDNA titres
Chris Wincup chriswincup ( View Tweet)
Congratulations to Dr. @VickiShanmugam, chair of ACR annual meeting planning subcommittee, @donna_hoyne VP of Education, and the whole team at ACR for putting on an outstanding conference in Chicago! #ACR18
Angus Worthing MD AngusWorthing ( View Tweet)
RheumNow expanded twitter coverage of the ACR 2018 Annual meeting sponsored in part by Horizon Pharma. All content chosen and distributed by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
*Fewer* wound complications and infections in RA patients continuing methotrexate throughout orthopedic surgeries. Let your ortho colleagues know this! #ACR18 @rheumnow https://t.co/eDtLvuE7Fw
Paul Sufka, MD psufka ( View Tweet)
Even low dose prednisone (5mg/day) associated with increased cumulative risk of infection #ACR18 @rheumnow https://t.co/UULnw8LCdW
Paul Sufka, MD psufka ( View Tweet)
Higher number of dominant B cell receptor clones in peripheral blood predicts the development from arthralgia to active disease in rheumatoid arthritis, de Vries N #acr18
Dr. Antoni Chan synovialjoints ( View Tweet)
Genetic Risk score prediction in Ankylosing Spondylitis using nearly 4000 SNPs in the European cohort showed performance as good as MRI screening and may help predict development of #ankylosingsponylitis Li Z #ACR18
Dr. Antoni Chan synovialjoints ( View Tweet)
Interesting study in this very hard to treat population MDAS positive ILD . Combined Tacrolimus and IV Cyclophosphamide have a better survival rate. But at the expense of higher risk of infections despite prophylaxis #ACR18 #CleClinicRheum https://t.co/aS0w8UQAME
Rula Hajj-Ali RulaHajjAliMD ( View Tweet)
Case reports prompted prospective trial from Tsuji H showing evidence of combined high dose GC + TAC + CYC beneficial in idiopathic inflammatory myopathy with interstitial lung disease and MDA-5 antibody #ACR18
Dr. Antoni Chan synovialjoints ( View Tweet)
Genetic predisposition to lupus in women may be contributed to by X chromosomes that encode TLR7 the receptor for RNA with B cell hyperproliferation when stimulated, Pascual M #sle #lupus #tlr #ACR18
Dr. Antoni Chan synovialjoints ( View Tweet)
Interesting study of JAK-1 inhibitor in ankylosing spondylitis #ankylosingspondylitis #rheum #ACR18 https://t.co/c423eXEfqx
Dr. Antoni Chan synovialjoints ( View Tweet)
METEOR registry analysis of data from 12 countries shows association between socioeconomic status of a country and disease activity in RA patients. Biologic DMARDs when available in poorer countries had less than expected effect on disease activity, Bergstra SA #ACR18
Dr. Antoni Chan synovialjoints ( View Tweet)
The RISE registry showed that for 50% of RA patients, medication remained unchanged over the follow-up period, despite moderate to high disease activity. The treatment least likely to be altered was the combination of MTX and a biologic, Curtis J #ACR18
Dr. Antoni Chan synovialjoints ( View Tweet)
REMORA app and wearables provided data that showed positive outcomes with better information about short-lived flares, better self-awareness of the disease and better conversations and more personalised care, Dixon W #ACR18
Dr. Antoni Chan synovialjoints ( View Tweet)
checkpoint inhibitor-related myositis associated with poor outcomes. #2976 @RheumNow @HealioRheum #ACR18
Cassandra Calabrese CCalabreseDO ( View Tweet)
Great summary in the @ACRheum Daily News of the ‘2018 Great Debate examines questions about hydroxychloroquine dosing guidelines’ #ACR18 https://t.co/ZKkrcixo5v
Paul Sufka, MD psufka ( View Tweet)